EVH vs HQY

For growth investors, HealthEquity, Inc.

(HQY) is the stronger pick with 9. 5% revenue growth year-over-year, versus -26. 6% for Evolent Health, Inc. (EVH). HealthEquity, Inc. (HQY) offers the better valuation at 34. 1x trailing P/E (21. 2x forward), making it the more compelling value choice. Analysts rate Evolent Health, Inc. (EVH) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, HealthEquity, Inc.

is actually cheaper at 21. 2x.

Over the past 5 years, HealthEquity, Inc.

(HQY) delivered a total return of +12. 7%, compared to -78. 4% for Evolent Health, Inc. (EVH). Over 10 years, the gap is even starker: HQY returned +228. 2% versus EVH's -63. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HealthEquity, Inc.

(HQY) is the lower-risk stock at 1. 04β versus Evolent Health, Inc. 's 1. 21β — meaning EVH is approximately 16% more volatile than HQY relative to the S&P 500. On balance sheet safety, HealthEquity, Inc. (HQY) carries a lower debt/equity ratio of 2% versus 2% for Evolent Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), HealthEquity, Inc.

(HQY) is pulling ahead at 9. 5% versus -26. 6% for Evolent Health, Inc. (EVH). On earnings-per-share growth, the picture is similar: HealthEquity, Inc. grew EPS 125. 7% year-over-year, compared to -525. 9% for Evolent Health, Inc.. Over a 3-year CAGR, HQY leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HealthEquity, Inc.

(HQY) is the more profitable company, earning 16. 4% net margin versus -28. 5% for Evolent Health, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HQY leads at 24. 6% versus -0. 2% for EVH. At the gross margin level — before operating expenses — HQY leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, HealthEquity, Inc.

(HQY) trades at 21. 2x forward P/E versus 31. 2x for Evolent Health, Inc. — 9. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EVH: 49. 1% to $6. 38.

In this comparison, EVH (2.

3% yield) pays a dividend. HQY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Evolent Health, Inc.

(EVH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), 2. 3% yield). Both have compounded well over 10 years (EVH: -63. 6%, HQY: +228. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

EVH pays a dividend while HQY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.